Clinical Trials Logo

Migraine Disorders clinical trials

View clinical trials related to Migraine Disorders.

Filter by:

NCT ID: NCT02616978 Completed - Migraine Clinical Trials

Retrospective Study on the Use of CEFALY® Device During Migraine Attacks

Start date: November 2015
Phase: N/A
Study type: Observational

This is an Internet survey to collect data on the use of the Cefaly device to treat migraine attacks in regular Cefaly users.

NCT ID: NCT02615314 Completed - Migraine Clinical Trials

Clinical Aspects of Patients With Benign Paroxysmal Positional Vertigo (BPPV) and Migraine

Start date: January 2015
Phase: N/A
Study type: Observational

The aim of this study is to analyze the clinical aspects of patients with BPPV associated with migraine. It is our purpose to clarify weather migraine is a risk factor for BPPV if the clinical aspect and the therapeutic outcome is different.

NCT ID: NCT02614378 Completed - Migraine Clinical Trials

Abortive Effect of an Ear Insufflator on Migraine

Start date: November 2015
Phase: N/A
Study type: Interventional

Evaluate the effectiveness of air insufflation in aborting (stopping) an acute episode of migraine and compare it with a placebo effect of using the same procedure but without active insufflation. The insufflation will be used when the subject is experiencing an acute episode of migraine to determine its ability to reduce, if not to completely eliminate the migraine symptoms. Subjects receiving the placebo treatment will be offered the active treatment during the subsequent episode of migraine.

NCT ID: NCT02614287 Completed - Migraine Clinical Trials

A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura

Start date: November 30, 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the longer term safety of the study drug known as galcanezumab in participants with episodic or chronic migraine.

NCT ID: NCT02614261 Completed - Chronic Migraine Clinical Trials

Evaluation of Galcanezumab in the Prevention of Chronic Migraine

REGAIN
Start date: November 30, 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.

NCT ID: NCT02614196 Completed - Migraine Clinical Trials

Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study

EVOLVE-2
Start date: December 4, 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine.

NCT ID: NCT02614183 Completed - Migraine Clinical Trials

Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study

EVOLVE-1
Start date: November 30, 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with episodic migraine.

NCT ID: NCT02605174 Completed - Clinical trials for Migraine With or Without Aura

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

SPARTAN
Start date: May 2016
Phase: Phase 3
Study type: Interventional

This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).

NCT ID: NCT02593097 Completed - Migraine Clinical Trials

Metformin for the Prevention of Episodic Migraine (MPEM)

MPEM
Start date: February 2016
Phase: Phase 3
Study type: Interventional

The investigators will evaluate the safety and efficacy of metformin for preventive treatment of migraine in a randomized, double-blind, placebo-controlled, crossover trial.

NCT ID: NCT02590939 Completed - Migraine Clinical Trials

Acute Treatment of Migraine With e-TNS

ACME
Start date: February 1, 2016
Phase: N/A
Study type: Interventional

The main objective of this study is to assess the efficacy of the Cefaly® device as an acute treatment of migraine attack in adult patients. The patients will be applied either an active or placebo external neurostimulation for 1 hour during a migraine attack, and will report the pain on a visual analog scale before and after the treatment.